Transcatheter edge-to-edge repair (TEER) for tricuspid and mitral regurgitation is now guided by 16 new APSC consensus statements, developed with ≥80% expert agreement.
The APSC provides 16 updated consensus statements to guide clinical practitioners in the Asia-Pacific region on the appropriate use of TEER for tricuspid and mitral regurgitation.
Since the publication of the 2021 Asian Pacific Society of Cardiology (APSC) consensus statements on the use of MitraClip for mitral regurgitation (MR), other transcatheter edge-to-edge repair (TEER) devices have been introduced for the treatment of both tricuspid regurgitation (TR) and MR. Hence, the APSC developed these consensus recommendations, with general cardiologists and internal medicine specialists practicing cardiology as the intended readers, to update the recommendations on the appropriate use of TEER in patients with TR or MR. The APSC expert panel reviewed and appraised the available evidence using the GRADE system. Consensus recommendations were developed and put to an online vote. Consensus was reached when at least 80% of votes for a given recommendation were in support of 'agree' or 'neutral', The resulting 16 statements provide guidance for clinical practitioners in the region on the evaluation and management of patients with TR or MR in the Asia-Pacific region who are being considered for TEER therapy.
Yeo et al. (Wed,) conducted a review in Tricuspid and Mitral Regurgitation. Transcatheter edge-to-edge repair (TEER) was evaluated. Transcatheter edge-to-edge repair (TEER) for tricuspid and mitral regurgitation is now guided by 16 new APSC consensus statements, developed with ≥80% expert agreement.